Tuesday, May 31, 2016

Canaccord ups Spectranetics price target to $23.50

Canaccord ups Spectranetics price target to $23.50

April 29, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills. […]

Canaccord starts CryoLife at buy

Canaccord starts CryoLife at buy

April 13, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday. “We recommend small-cap GARP (growth at a reasonable price) investors build positions in CryoLife, which is actively building a cardiac surgery-focused company through targeted acquisitions that augment its strong, existing […]

Canaccord downgrades AngioDynamics to hold

Canaccord downgrades AngioDynamics to hold

April 5, 2016 by · Leave a Comment 

Tweet Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten investor concern near term, and increase uncertainty.” The stock closed at $12.14 on Monday. “What’s more, this change compounds myriad existing challenges […]

Canaccord starts Penumbra at buy

Canaccord starts Penumbra at buy

October 13, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Penumbra (NYSE:PEN) with a “buy” rating and 12-month target price of $48, representing 20% upside potential over the next year. The stock closed at $39.14 on Monday. “There have been few times in our nearly two decades analyzing the med-tech industry that we have seen a small-cap company […]

Canaccord starts Vermillion at buy

Canaccord starts Vermillion at buy

August 11, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of Vermillion (NASDAQ:VRML) with a “buy” rating and $4 price target. The stock closed at $1.89 on Monday. “We believe Vermillion is on track to expand into a high-value, diversified women’s health diagnostics company and is focused initially on ovarian cancer,” writes analyst Mark Massaro. “While we like the […]

Analysts raise price target for LeMaitre Vascular

Analysts raise price target for LeMaitre Vascular

July 29, 2015 by · Leave a Comment 

Tweet Canaccord Genuity and Roth Capital Partners have raised their price targets for LeMaitre Vascular (NASDAQ:LMAT) to $14.50 from $13, and to $14 from $11, respectively, after the company set another record sales quarter. The stock closed at $11.24 on Tuesday. “We continue to view LeMaitre as one of the most undervalued small-cap stocks in […]

Leerink, Canaccord launch coverage of HTG Molecular

Leerink, Canaccord launch coverage of HTG Molecular

June 2, 2015 by · Leave a Comment 

Tweet Analysts at Leerink Partners and Canaccord Genuity have initiated coverage of HTG Molecular Diagnostics (NASDAQ:HTGM) with “outperform” and “buy” ratings, respectively, and price targets of $18 and $17, respectively. The stock closed at $13.91 on Monday. “We believe in the company’s strong and deep management team and strong early relationships with big pharma, biotech, […]

Canaccord starts Neovasc at buy

Canaccord starts Neovasc at buy

April 2, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of Neovasc (NASDAQ:NVCN; TSX:NVC) with a “buy” rating and 12-month target price of $15. The stock closed at $8.99 on Wednesday. Neovasc is one of the early leaders in the burgeoning transcatheter mitral valve replacement (TMVR) space, writes analyst Jason Mills. Its proprietary Tiara valve has demonstrated encouraging results […]

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). The company also has a second drug candidate, Actimab-A, now in a […]

Canaccord starts Avinger at buy

Canaccord starts Avinger at buy

February 24, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Avinger (NASDAQ:AVGR) with a “buy” rating and price target of $18. The stock closed at $10.66 on Monday. “Avinger checks the most important boxes that we look for in a small-cap med-tech growth stock,” writes analyst Jason Mills. He said Avinger targets a large, under-penetrated and growing addressable […]

Next Page »

Email Newsletters with Constant Contact
Google+